ArticlePediatric rheumatology online journal2026
Elevated nil values in TB-IGRA: a potential diagnostic clue for pediatric histiocytic necrotizing lymphadenitis.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistiocytic necrotizing lymphadenitis (HNL) is a benign condition in children that is often misdiagnosed due to its clinical overlap with tuberculosis, rheumatic diseases, and lymphadenitis. The QuantiFERON-TB Gold In-Tube assay (TB-IGRA) is routinely used to rule out tuberculosis, but its Nil value (TB-Nil), which reflects background IFN-γ release, remains underutilized. Many studies suggest that elevated IFN-γ levels may aid in the differential diagnosis of HNL. In this study, we investigate the role of TB-Nil in diagnosing HNL.
methodsTo investigate the relationship between TB-Nil values and the diagnosis of HNL, we retrospectively enrolled 48 patients who were diagnosed with HNL at the Women and Children's Medical Center, Guangzhou Medical University, between January 2019 and December 2024 and who had undergone TB-IGRA testing. Clinical data were extracted from the electronic medical record system. TB-Nil values were compared between HNL and other common causes of lymphadenitis, including systemic juvenile idiopathic arthritis (sJIA), Kawasaki disease (KD), and bacterial lymphadenitis (BL). Receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic performance.
resultsAmong the 48 enrolled patients with suspected HNL, 37 were confirmed by pathological diagnosis and the remaining 11 were diagnosed based on clinical criteria. The median Nil level was significantly elevated in HNL patients [0.82 IU/mL, interquartile range (IQR): 0.36-1.18] compared with patients with systemic juvenile idiopathic arthritis (sJIA, median = 0.07 IU/mL, P < 0.0001), Kawasaki disease (KD, median = 0.09 IU/mL, P < 0.0001) and Bacterial Lymphadenitis (BL, median = 0.09 IU/mL, P < 0.0001). Receiver operating characteristic (ROC) curve analysis revealed favorable diagnostic performance of the Nil index for identifying HNL, with an AUC of 0.8781 (95%CI: 0.8138-0.9424). The optimal cutoff value of TB-Nil was determined as 0.19 IU/mL for distinguishing HNL from the three control diseases (sJIA, KD and BL), corresponding to a sensitivity of 78.38% and a specificity of 91.67%.
conclusionThe routinely available yet often overlooked Nil value from the TB-IGRA is significantly elevated in pediatric HNL and demonstrates favorable diagnostic accuracy. It may serve as a practical, non-invasive adjunctive biomarker for the early differential diagnosis of HNL from other inflammatory diseases. Prospective multi-center studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.